about
THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis studyEffects of testosterone on sexual function in men: results of a meta-analysis.Coordinating care aspects related to sexual health in the aging male.The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil.Leptin in reproduction.Testosterone and metabolic syndrome: a meta-analysis study.Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine?Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review.Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions.Androgen deficiency and hormone-replacement therapy.Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction.Negative association between trunk fat, insulin resistance and skeleton in obese women.Chronic sildenafil in men with diabetes and erectile dysfunction.The role of penile color-duplex ultrasound for the evaluation of erectile dysfunction.Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction.The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction.Endothelial effects of drugs designed to treat erectile dysfunction.Trunk fat negatively influences skeletal and testicular functions in obese men: clinical implications for the aging male.Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome.Endothelial dysfunction and erectile dysfunction in the aging man.Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation?Onset of effects of testosterone treatment and time span until maximum effects are achievedThe controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation.An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.CAG repeat testing of androgen receptor polymorphism: is this necessary for the best clinical management of hypogonadism?Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions.Testosterone supplementation and sexual function: a meta-analysis study.Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis.Age-associated (cardio)metabolic diseases and cross-talk between adipose tissue and skeleton: endocrine aspects.Endocrinologic Control of Men's Sexual Desire and Arousal/Erection.Peripheral arterial tonometry to measure the effects of vardenafil on sympathetic tone in men with lifelong premature ejaculation.The application of digital pulse amplitude tonometry to the diagnostic investigation of endothelial dysfunction in men with erectile dysfunction.Erectile dysfunction of sclerodermic patients correlates with digital vascular damage.Is late-onset hypogonadotropic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden?Erectile dysfunction, endothelium dysfunction, and microvascular damage in patients with systemic sclerosis.Penile involvement in Systemic Sclerosis: New Diagnostic and Therapeutic Aspects.Systemic and metabolic effects of PDE5-inhibitor drugsCardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: effects of 3 years intermittent testosterone supplementation.
P50
Q26780084-5781FE8C-DE97-4DC4-B3AE-4F828F8D8A54Q33223876-677F73D0-A603-4A1A-8125-78C6D22FDA2CQ33563337-6D83228A-4E28-4187-8912-ADA444BB83F2Q33737324-71872CD3-12B9-4B84-82EC-6A6D50DD5383Q34135055-2AD89A0C-05AD-4789-9F5C-A06D7DC69A43Q34135149-C1DB3849-9511-4AD2-BD01-39A366DC0F56Q35076387-BA9BBA9F-F6FF-49B0-A580-BA03CD2DCAFCQ35810322-A4038E41-4EC4-4907-9014-6B48F91CD1AFQ36055080-C62DCCC4-1E47-4F05-9B75-4C2C6F1D2783Q36185648-5A97338C-9CFC-42E5-88FB-6F9FB4FA7AACQ36595939-7C81EE28-3B0D-4EC9-B4CB-0EE714F3CA2AQ36612072-7AC05995-9458-4F3C-B208-360D48599306Q36739886-F5A6A86D-B624-4CB6-96EC-72B125D8976CQ36768908-5305D188-8498-4C6A-9E3C-8BB550AE98C1Q36835843-DC986DD0-9F28-47B5-A93B-9B8B4BA2A8E5Q36889045-092197C3-EDF9-4EC3-B3DD-48B94928898EQ37065895-B775CFEC-DA99-4E06-B5F6-BA96113947AEQ37364037-6953CD14-27E9-4A23-888F-0770827C0BFDQ37364042-33CF6D03-EBF9-458D-A243-FEB1A33ACCFBQ37372062-C7B2882F-4944-4565-BCBF-A1AA8EB3545FQ37622016-412218F1-2E66-46A3-BBE5-A54012D8A0E1Q37650850-106211FE-E10D-4839-8247-CCD047EC91C2Q37832643-F190CC2A-151E-4381-B64B-BCD090F93EB0Q37900796-66F807EA-71E7-44CA-A8B7-A5794E54D04EQ37905963-7B3FBAD5-934C-43EF-B7F3-CC28C60F1CA1Q38107001-23AE5F26-4695-4364-9B2D-14B57D44ED96Q38120781-83932FE9-D086-42FC-811E-F1A59E99B2B8Q38151247-7BC94765-2ADB-4852-8783-95C623BBE130Q38201813-AC0610E7-1E8C-4B6E-B5F3-FBA2525DFD4BQ38256241-50DECEA4-BF5E-4DDB-B9EC-9B5B997C888EQ38280509-8777099F-876B-4B52-8130-5E717D3C6C30Q38761258-D22DF939-FF06-463E-A4C8-C1EC6CB3911FQ39768026-B8003A52-99E2-471A-9160-4E52F5211D16Q39965970-982A6A2B-FCE2-4B73-8859-F93D0BA6519DQ39983034-EC3F4367-C089-4178-8CC7-2530B8AC397AQ39992231-B4FC10B5-566D-47AD-A8FE-2E31FFC52B44Q40094889-21903F2F-299A-4011-BE00-6ED96D8B7230Q41815275-285CE9A3-AC12-478B-9DF3-B3FC26182AFEQ42129412-E8BA5E21-23C7-404C-8EAA-607940AA6457Q42174870-8E09D85F-96D6-45D0-8181-AB6D84393A1D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonio Aversa
@ast
Antonio Aversa
@en
Antonio Aversa
@es
Antonio Aversa
@it
Antonio Aversa
@nl
Antonio Aversa
@sl
type
label
Antonio Aversa
@ast
Antonio Aversa
@en
Antonio Aversa
@es
Antonio Aversa
@it
Antonio Aversa
@nl
Antonio Aversa
@sl
altLabel
@DrAversa
@en
prefLabel
Antonio Aversa
@ast
Antonio Aversa
@en
Antonio Aversa
@es
Antonio Aversa
@it
Antonio Aversa
@nl
Antonio Aversa
@sl
P106
P1153
7004221169
P21
P2798
P31
P496
0000-0002-2989-2618